129 related articles for article (PubMed ID: 30352869)
21. Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?
Lobo J; Pinto C; Freitas M; Pinheiro M; Vizcaino R; Oliva E; Teixeira MR; Jerónimo C; Bartosch C
Virchows Arch; 2017 Mar; 470(3):347-352. PubMed ID: 27915441
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
23. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
24. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters.
Hashmi AA; Mudassir G; Hashmi RN; Irfan M; Asif H; Khan EY; Abu Bakar SM; Faridi N
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2601-2606. PubMed ID: 31554352
[TBL] [Abstract][Full Text] [Related]
25. A new mutL homolog 1 c.1896+5G>A germline mutation detected in a Lynch syndrome-associated lung and gastric double primary cancer patient.
Chen X; Li X; Liang H; Wei L; Cui Q; Yao M; Wu X
Mol Genet Genomic Med; 2019 Aug; 7(8):e787. PubMed ID: 31207149
[TBL] [Abstract][Full Text] [Related]
26. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
27. MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas.
Chen W; Pearlman R; Hampel H; Pritchard CC; Markow M; Arnold C; Knight D; Frankel WL
Hum Pathol; 2020 Feb; 96():104-111. PubMed ID: 31783044
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of synchronous chemoresistant pulmonary metastasis from pleomorphic rhabdomyosarcoma with stereotaxic body radiation therapy: A case report and a review of the literature.
Benkhaled S; Mané M; Jungels C; Shumelinsky F; Aubain NS; Van Gestel D
Cancer Treat Res Commun; 2021; 26():100282. PubMed ID: 33360328
[TBL] [Abstract][Full Text] [Related]
29. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
[TBL] [Abstract][Full Text] [Related]
30. Gene-Specific Variation in Colorectal Cancer Surveillance Strategies for Lynch Syndrome.
Kastrinos F; Ingram MA; Silver ER; Oh A; Laszkowska M; Rustgi AK; Hur C
Gastroenterology; 2021 Aug; 161(2):453-462.e15. PubMed ID: 33839100
[TBL] [Abstract][Full Text] [Related]
31. Germline variants screening of MLH1, MSH2, MSH6 and PMS2 genes in 64 Algerian Lynch syndrome families: The first nationwide study.
Boumehdi AL; Cherbal F; Khider F; Oukkal M; Mahfouf H; Zebboudj F; Maaoui M
Ann Hum Genet; 2022 Nov; 86(6):328-352. PubMed ID: 36073783
[TBL] [Abstract][Full Text] [Related]
32. Implication of DNA repair genes in Lynch-like syndrome.
Xicola RM; Clark JR; Carroll T; Alvikas J; Marwaha P; Regan MR; Lopez-Giraldez F; Choi J; Emmadi R; Alagiozian-Angelova V; Kupfer SS; Ellis NA; Llor X
Fam Cancer; 2019 Jul; 18(3):331-342. PubMed ID: 30989425
[TBL] [Abstract][Full Text] [Related]
33. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
34. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
35. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.
Goel A; Nguyen TP; Leung HC; Nagasaka T; Rhees J; Hotchkiss E; Arnold M; Banerji P; Koi M; Kwok CT; Packham D; Lipton L; Boland CR; Ward RL; Hitchins MP
Int J Cancer; 2011 Feb; 128(4):869-78. PubMed ID: 20473912
[TBL] [Abstract][Full Text] [Related]
36. Contribution of MLH1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor MLH1 downregulation.
Pinto D; Pinto C; Guerra J; Pinheiro M; Santos R; Vedeld HM; Yohannes Z; Peixoto A; Santos C; Pinto P; Lopes P; Lothe R; Lind GE; Henrique R; Teixeira MR
Cancer Med; 2018 Feb; 7(2):433-444. PubMed ID: 29341452
[TBL] [Abstract][Full Text] [Related]
37. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
[TBL] [Abstract][Full Text] [Related]
38. The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma.
Gabrych A; Pęksa R; Kunc M; Krawczyk M; Izycka-Swieszewska E; Biernat W; Bień E
Pathol Res Pract; 2019 Dec; 215(12):152700. PubMed ID: 31704149
[TBL] [Abstract][Full Text] [Related]
39. Loss of DNA mismatch repair proteins in prostate cancer.
Sharma M; Yang Z; Miyamoto H
Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
[TBL] [Abstract][Full Text] [Related]
40. Assessment of mismatch repair deficiency in ovarian cancer.
Crosbie EJ; Ryan NAJ; McVey RJ; Lalloo F; Bowers N; Green K; Woodward ER; Clancy T; Bolton J; Wallace AJ; McMahon RF; Evans DG
J Med Genet; 2021 Oct; 58(10):687-691. PubMed ID: 32917768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
